Cancer Nanotechnology

According to the World Health Organization (WHO), there will be 15 million new cases of cancer worldwide in 2020. More than 90% of cancer-related deaths occur by the spread of malignant cells to vital organs, a process called metastasis. Academia, Pharmaceutical and biotechnology companies are making substantial research investments in order to develop specific treatments that can destroy primary and secondary tumors, i.e. those resulting from metastasis to other organs. Nanotechnology in cancer treatments is already a reality providing a wide range of new tools and possibilities, from earlier diagnostics and improved imaging to better, more efficient, and more targeted therapies.

 

  • Detection & Diagnosis
  • Treatment & Therapy
  • Safety of Nanotechnology

Related Conference of Cancer Nanotechnology

April 04-05, 2024

17th European Biosimilars Congress

Madrid, Spain
April 11-12, 2024

5th Annual Congress on Antibiotics and Bacterial Infections

Amsterdam, Netherlands
May 09-10, 2024

4th Global Summit on Pharmaceutical Research

Barcelona, Spain
May 16-17, 2024

18th World Drug Delivery Summit

Rome, Italy
May 30-31, 2024

9th Pharmaceutical Chemistry Conference

Paris, France
July 25-26, 2024

34th Annual European Pharma Congress

Frankfurt, Germany
September 11-12, 2024

9th International Conference on Future Pharma and Innovations

Amsterdam, Netherlands
September 25-26, 2024

4th World Congress on Rare Diseases & Orphan Drugs

Paris, France
November 26-27, 2024

3rd World Conference on Pharma Industry and Medical Devices

Zurich, Switzerland
November 26-27, 2024

3rd World Congress on Precision and Personalized Medicine

Zurich, Switzerland
November 28-29, 2024

39th World Congress on Pharmacology and Therapeutics

Paris, France
November 28-29, 2024

12th International Conference on Clinical Trials

Vancouver, Canada
December 05-06, 2024

17th World Drug Delivery Summit

Dubai, UAE

Cancer Nanotechnology Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in